Logo

GSK's Nucala (mepolizumab) Receives the US FDA's Approval as First Biologic for Severe Eosinophilic Asthma in Children Aged 6-11yrs.

Share this

GSK's Nucala (mepolizumab) Receives the US FDA's Approval as First Biologic for Severe Eosinophilic Asthma in Children Aged 6-11yrs.

Shots:

  • The US FDA’s approval follows the open-label study evaluating PK/PD and long-term safety of Nucala (40mg- SC) in children with severe eosinophilic asthma aged 6 to 11yrs. The approval is also supported by results of well-controlled studies assessing Nucala in adults and adolescents
  • The 52wks. long term study of Nucala in pediatric patients aged 6-11yrs. is similar to a safety profile in patients aged ≥12yrs.
  • Nucala (100mg- SC) is mAb targeting IL-5- approved as an add-on maintenance therapy for severe eosinophilic asthma patients aged ≥12yrs. in 2015. In Aug 2018- Nucala has received approval as an add-on treatment for severe eosinophilic asthma in patients aged 6-11yrs. in the EU

Click here to­ read full press release/ article

Ref: GSK | Image: GSK


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions